

AMENDMENTS TO THE CLAIMS

1.-33. (Canceled)

34. (Previously Presented) A method for producing an RNA molecule which is capable of delaying, repressing or otherwise reducing the expression of a target gene in an isolated eukaryotic cell comprising introducing into an isolated eukaryotic cell a synthetic genetic construct comprising two copies of a structural gene sequence operably under the control of a single promoter and a terminator sequence which contains a polyadenylation signal and is active in the cell, wherein said structural gene sequence comprises a nucleotide sequence which is identical to a sequence of 30 contiguous nucleotides of said target gene, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation and at least one other copy of said structural gene sequence is placed operably in the antisense orientation under the control of the promoter; wherein said two copies of said structural gene sequence are spatially separated by a stuffer fragment which comprises a sequence of nucleotides, and wherein the synthetic genetic construct is transcribed to produce the RNA molecule.

35.-87. (Canceled)

88. (Previously Presented) The method of claim 34, wherein the target gene is a viral gene.

89. (Previously Presented) The method of claim 34, wherein the cell is a plant cell.

3668892

90. (Previously Presented) The method of claim 89, wherein the target gene is a viral gene.
91. (Previously Presented) The method of claim 88, wherein the viral gene encodes a DNA polymerase, RNA polymerase or viral coat protein.
92. (Previously Presented) The method of claim 34, wherein the target gene is from a lentivirus.
93. (Previously Presented) The method of claim 34, wherein the target gene is from an immuno deficiency virus.
94. (Previously Presented) The method of claim 34, wherein the target gene is from a single-stranded (+) RNA virus.
95. (Previously Presented) The method of claim 34, wherein the target gene is from a double-stranded DNA virus.
96. (Previously Presented) The method of claim 34, wherein the target gene is a transgene in the cell.
97. (Previously Presented) the method of claim 34, wherein the target gene is an endogenous gene of the cell.

98. (Previously Presented) The method of claim 97, wherein the cell is a plant cell.
99. (Previously Presented) The method of claim 97, wherein the cell is an animal cell.
100. (Previously Presented) The method of claim 34, wherein the contiguous nucleotides of the target gene corresponds to a coding region of the target gene.
101. (Previously Presented) The method of claim 34, wherein the 30 contiguous nucleotides of the target gene corresponds to a 5' or 3' – untranslated sequence of the target gene.
102. (Previously Presented) The method of claim 34, wherein the transcribed region of the genetic construct comprises an intron.
103. (Previously Presented) The method of claim 34, wherein the stuffer fragment is a sequence of nucleotides 10-50 nucleotides in length, 50-100 nucleotides in length, or 100-500 nucleotides in length.
104. (Previously Presented) The method of claim 34, wherein the stuffer fragment comprises an intron.
105. (Previously Presented) The method of claim 34, wherein the total length of said structural gene sequences is no more than 2.0 kilobases.

106. (Previously Presented) The method of claim 34, wherein the total length of said structural gene sequences is no more than 0.5 kilobases.
107. (Previously Presented) The method of claim 34, wherein the two copies are in a head-to-head orientation relative to each other.
108. (Previously Presented) The method of claim 34, wherein the two copies are in a tail-to-tail orientation relative to each other.
109. (Previously Presented) The method of claim 34, comprising transfecting the cell with the genetic construct.
110. (Previously Presented) The method of claim 34, wherein the genetic construct is delivered to the cell in a virus particle.
111. (Previously Presented) The method of claim 34, wherein the genetic construct is delivered to the cell in a liposome.
112. (Previously Presented) The method of claim 34, wherein the genetic construct is integrated into the genome of the cell.
113. (Previously Presented) The method of claim 34, wherein the genetic construct has only two copies of said structural gene sequence.

AMENDMENTS TO THE CLAIMS

1.-33. (Canceled)

34. (Previously Presented) A method for producing an RNA molecule which is capable of delaying, repressing or otherwise reducing the expression of a target gene in an isolated eukaryotic cell comprising introducing into an isolated eukaryotic cell a synthetic genetic construct comprising two copies of a structural gene sequence operably under the control of a single promoter and a terminator sequence which contains a polyadenylation signal and is active in the cell, wherein said structural gene sequence comprises a nucleotide sequence which is identical to a sequence of 30 contiguous nucleotides of said target gene, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation and at least one other copy of said structural gene sequence is placed operably in the antisense orientation under the control of the promoter; wherein said two copies of said structural gene sequence are spatially separated by a stuffer fragment which comprises a sequence of nucleotides, and wherein the synthetic genetic construct is transcribed to produce the RNA molecule.

35.-87. (Canceled)

88. (Previously Presented) The method of claim 34, wherein the target gene is a viral gene.

89. (Previously Presented) The method of claim 34, wherein the cell is a plant cell.

90. (Previously Presented) The method of claim 89, wherein the target gene is a viral gene.
91. (Previously Presented) The method of claim 88, wherein the viral gene encodes a DNA polymerase, RNA polymerase or viral coat protein.
92. (Previously Presented) The method of claim 34, wherein the target gene is from a lentivirus.
93. (Previously Presented) The method of claim 34, wherein the target gene is from an immuno deficiency virus.
94. (Previously Presented) The method of claim 34, wherein the target gene is from a single-stranded (+) RNA virus.
95. (Previously Presented) The method of claim 34, wherein the target gene is from a double-stranded DNA virus.
96. (Previously Presented) The method of claim 34, wherein the target gene is a transgene in the cell.
97. (Previously Presented) the method of claim 34, wherein the target gene is an endogenous gene of the cell.

98. (Previously Presented) The method of claim 97, wherein the cell is a plant cell.
99. (Previously Presented) The method of claim 97, wherein the cell is an animal cell.
100. (Previously Presented) The method of claim 34, wherein the contiguous nucleotides of the target gene corresponds to a coding region of the target gene.
101. (Previously Presented) The method of claim 34, wherein the 30 contiguous nucleotides of the target gene corresponds to a 5' or 3' – untranslated sequence of the target gene.
102. (Previously Presented) The method of claim 34, wherein the transcribed region of the genetic construct comprises an intron.
103. (Previously Presented) The method of claim 34, wherein the stuffer fragment is a sequence of nucleotides 10-50 nucleotides in length, 50-100 nucleotides in length, or 100-500 nucleotides in length.
104. (Previously Presented) The method of claim 34, wherein the stuffer fragment comprises an intron.
105. (Previously Presented) The method of claim 34, wherein the total length of said structural gene sequences is no more than 2.0 kilobases.

106. (Previously Presented) The method of claim 34, wherein the total length of said structural gene sequences is no more than 0.5 kilobases.
107. (Previously Presented) The method of claim 34, wherein the two copies are in a head-to-head orientation relative to each other.
108. (Previously Presented) The method of claim 34, wherein the two copies are in a tail-to-tail orientation relative to each other.
109. (Previously Presented) The method of claim 34, comprising transfecting the cell with the genetic construct.
110. (Previously Presented) The method of claim 34, wherein the genetic construct is delivered to the cell in a virus particle.
111. (Previously Presented) The method of claim 34, wherein the genetic construct is delivered to the cell in a liposome.
112. (Previously Presented) The method of claim 34, wherein the genetic construct is integrated into the genome of the cell.
113. (Previously Presented) The method of claim 34, wherein the genetic construct has only two copies of said structural gene sequence.



114. (Previously Presented) A method for producing an RNA molecule which is capable of delaying, repressing or otherwise reducing the expression of a target gene in a plant cell comprising introducing into the plant cell a synthetic genetic construct comprising two copies of a structural gene sequence operably under the control of a single promoter and a terminator sequence which contains a polyadenylation signal and is active in the cell, wherein said structural gene sequence comprises a nucleotide sequence which is identical to a sequence of 30 contiguous nucleotides of said target gene, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation and at least one other copy of said structural gene sequence is placed operably in the antisense orientation under the control of the promoter; wherein said two copies of said structural gene sequence are spatially separated by a stuffer fragment which comprises a sequence of nucleotides, and wherein the synthetic genetic construct is transcribed to produce the RNA molecule.

115. (Previously Presented) The method of claim 114, wherein the target gene is a viral gene.

116. (Previously Presented) The method of claim 115, wherein the viral gene encodes a DNA polymerase, RNA polymerase or viral coat protein

117. (Currently Amended) The method of claim ~~11~~114, wherein the target gene is from a single-stranded (+) RNA virus.

118. (Currently Amended) The method of claim ~~11~~114, wherein the target gene is from a double-stranded DNA virus.

119. (Currently Amended) The method of claim ~~11~~114, wherein the target gene is a transgene in the cell.

120. (Currently Amended) The method of claim ~~11~~114, wherein the target gene is an endogenous gene of the cell.

121. (Currently Amended) The method of claim ~~11~~114, wherein the 30 contiguous nucleotides of the target gene corresponds to a coding region of the target gene.

122. (Currently Amended) The method of claim ~~11~~114, wherein the 30 contiguous nucleotides of the target gene corresponds to a 5'- or 3'- untranslated sequence of the target gene.

123. (Currently Amended) The method of claim ~~11~~114, wherein the transcribed region of the genetic construct comprises an intron.

124. (Currently Amended) The method of claim ~~11~~114, wherein the stuffer fragment is a sequence of nucleotides 10-50 nucleotides in length, 50-100 nucleotides in length, or 100-500 nucleotides in length.

125. (Previously Presented) The method of claim 114, wherein the stuffer fragment comprises an intron.

126. (Currently Amended) The method of claim ~~11~~114, wherein the total length of said structural gene sequences is no more than 2.0 kilobases.

127. (Previously Presented) The method of claim 126, wherein the total length of said structural gene sequences is no more than 0.5 kilobases.

128. (Currently Amended) The method of claim ~~11~~114, wherein the two copies are in a head-to-head orientation relative to each other.

129. (Currently Amended) The method of claim ~~11~~114, wherein the two copies are in a tail-to-tail orientation relative to each other.

130. (Currently Amended) The method of claim ~~11~~114, wherein the genetic construct is integrated into the genome of the cell.

131. (Currently Amended) The method of claim ~~11~~114, wherein the genetic construct has only two copies of said structural gene sequence.

132. (Previously Presented) The method of claim 114, wherein the cell is comprised in a transgenic plant.